Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment

NCT00455221 is registered in ClinicalTrials.gov with Tehran University of Medical Sciences as lead sponsor.

NCT NCT00455221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment
Lead sponsor
Tehran University of Medical Sciences
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
November 30, 2011
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, chronic